A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion
cohort study designed to evaluate the safety and antitumor activity of BDTX-4933. The study
population comprises adults with recurrent advanced/metastatic cancers harboring BRAF (Class
I, II, and III), KRAS (other than G12C such as G12D, G12V), or NRAS mutations including
non-small cell lung cancer (NSCLC), melanoma, histiocytic neoplasms, thyroid cancer,
colorectal cancer, and other solid tumor cancers with or without brain metastases. All
patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression,
toxicity, withdrawal of consent, or termination of the study.